A model-based comparison of cost effectiveness of imiquimod versus podophyllotoxin for the treatment of external anogenital warts in France;Comparaison coût-emcacité par modélisation de l'imiquimod et de la podophyllotoxine dans le traitement du condylome acuminé externe en France

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 8-9 I, 2003, Pages 731-736

  Lafuma, A ^a   Monsonego, J ^b   Moyal Barracco, M ^c   Pribil, C ^a  

^a CEMKA EVAL   (France)

^b INSTITUT ALFRED FOURNIER   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; PODOPHYLLOTOXIN;

ADULT; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FRANCE; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MONEY; OUTCOMES RESEARCH; RELAPSE; REMISSION; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 0142119475     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Center for Disease Control and Prevention Division of STD/HIV prevention. Annual Report. Atlanta GA: Department of Health and Human Services 1994.
2. Persson G, Andersson K, Krantz I. Symptomatic genital papillomavirus infection in a community. Acta Obstet Gynecol Scand 1996;75:287-90.
3. Heather Lyttle P. Surveillance report: disease trends at New Zealand sexually-transmitted disease clinics. Genitourin Med 1994;70:329-35.
4. Koutsky LA, Gallowey DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-63.
5. Monsonego J, Zerat L, Catalan F, Coscas Y. Genital Human papillomavirus infections: correlation of cytological, colposcopic and histological features with viral types in females and their male partners Int J STD AIDS 1993;4:13-20.
6. Chuang TY, Perry HO, Kurland LT, Ilstrup DM. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. Arch Dermatol 1984;120:469-75.
7. Kraus S, Stone KM. Management of genital infection caused by human papillomavirus. Rev Infect Dis 1990;12:620-32.
8. Langley PC, Tyring SK, Smith MH. The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Managed Care 1999;5:69-77.
9. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL et al. Self-administered topical 5% imiquimod Cream for external anogenital warts. Arch Dermatol 1998;134:25-30.
10. Tyring S, Edwards L, Cherry LK, Ramsdell WM, Kotner S, Greenberg MD et al. Safety and efficacy of 0.5% Podofilox gel in the treatment of anogenital wart. Arch Dermatol 1998;134:33-8.
11. Beutner KR, Conant MA, Friedman-Kien AE, Illeman M, Artman NN et al. Patient-applied podofilox for treatment of genital warts. Lancet 1989;1:831-4.
12. Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK Jr. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991;77:735-9.
13. Sheldon TA. Problems of using modeling in the economic evaluation of health care. Health Econ 1996;5:1-11.
14. Carpiniello VL, Malloy TR, Sedlacek TV, Zderic SA. Results of carbon dioxide laser therapy and topical 5-fluorouracil treatment for subclinical condyloma found by magnified penile surface scanning. J Urol 1988;140: 53-4.
15. The Condylomata International Collaborative Study Group. A comparison of interferon alpha-2a and podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1991;67:394-9.
16. Petersen CS, Bjerring P, Larsen J, Blaakaer J, Hagdrup H, From E et al Systemic Interferon alpha-2b increases the cure rate in laser treated patients with multiple persistent genital warts: a placebo-controlled study. Genitourin Med 1991;67:99-102.
17. Reid R, Greenberg MD, Pizzuti DJ, Omoto KH, Rutledge LH, Soo W. Superficial laser vulvectomy. Surgical debulking is enhanced by adjuvent systemic interferon. Am J Obstet Gynecol 1992;166:815-20.